𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response

✍ Scribed by Sutharshan, K.; Gearry, R.B.

Book ID
122663635
Publisher
Oxford University Press
Year
2013
Tongue
English
Weight
242 KB
Volume
7
Category
Article
ISSN
1873-9946

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Predictors of adalimumab dose escalation
Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 167 KB πŸ‘ 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require